Remittix Presale Nears End as Pepeto Holders Flock to Final Stages

Medicus Pharma announced a Phase 2 study demonstrating 73% clinical clearance in the 200-µg arm of its SkinJect microneedle platform for basal cell carcinoma treatment. Principal Investigator Babar K. Rao, MD, FAAD, will provide clinical interpretation of the data during a business update webcast on March 26. The positive results suggest that approximately three out of four treated lesions may allow patients to avoid immediate surgical intervention.